Drug Trial Radar · NCT04036435
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,466
Actual
Start
Aug 12, 2019
Primary completion
Jul 21, 2026
Study completion Jul 21, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have been previously enrolled in an applicable Phase 3 psoriasis study. In addition, the study includes a vaccine cohort to evaluate whether deucravacitinib impacts the humoral immune response to 2 non-live vaccines, the Pneumovax 23 vaccine (pneumococcus), a T-cell independent vaccine, and the Boostrix vaccine (tetanus toxoid), a T-cell dependent vaccine. Additionally, this vaccine cohort assesses the safety of administering these vaccines to subjects with psoriasis receiving deucravacitinib compared to those receiving a placebo.
Conditions
- Psoriasis
Interventions
BMS-986165Drug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Up to 244 weeks
- Incidence of Serious Adverse Events (SAEs)Time frame: Up to 244 weeks
- Proportion of participants achieving a satisfactory humoral response: pneumococcusTime frame: At Week 4 post vaccination
- Proportion of participants achieving a satisfactory humoral response: tetanus titersTime frame: At Week 4 post vaccination
Locations
302 sites in 20 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center
Birmingham, Alabama
Local Institution - 0278
Birmingham, Alabama
Alliance Dermatology and Mohs Center - Phoenix
Phoenix, Arizona
Arizona Research Center
Phoenix, Arizona
Synexus - Orange Grove Family Practice
Tucson, Arizona
Johnson Dermatology
Fort Smith, Arkansas
Burke Pharmaceutical Research
Hot Springs, Arkansas
Northwest Arkansas Clinical Trials Center, PLLC
Rogers, Arkansas
Local Institution - 0046
Fountain Valley, California
Local Institution - 0206
Fresno, California
Local Institution - 0017
Irvine, California
Interspond - Long Beach Clinical Trials
Long Beach, California
Dermatology Research Associates - Los Angeles
Los Angeles, California
Local Institution - 0236
Los Angeles, California
University of California San Diego Health Systems
San Diego, California
Therapeutics Clinical Research
San Diego, California
University Dermatology Group
San Diego, California
Local Institution - 0094
San Luis Obispo, California
Clinical Science Institute
Santa Monica, California
NorthBay Clinical Research
Santa Rosa, California
Synexus - Santa Rosa
Santa Rosa, California
Local Institution - 0042
Sherman Oaks, California
Care Access Research - Walnut Creek
Walnut Creek, California
New England Research Associates
Bridgeport, Connecticut
Stamford Therapeutics Consortium
Stamford, Connecticut
Local Institution - 0170
Boca Raton, Florida
ERN - Accel Research Sites
DeLand, Florida
Indago Research and Health Center
Hialeah, Florida
LCC Medical Research
Miami, Florida
International Dermatology Research
Miami, Florida
Well Pharma Medical Research
Miami, Florida
Local Institution - 0216
Miami, Florida
Interspond - Savin Medical Group
Miami Lakes, Florida
Local Institution - 0007
Miami Lakes, Florida
Local Institution - 0198
Port Orange, Florida
Local Institution - 0233
Tampa, Florida
Local Institution - 0008
Tampa, Florida
Local Institution - 0013
Marietta, Georgia
Local Institution - 0235
Sandy Springs, Georgia
Treasure Valley Dermatology & Skin Cancer Center
Meridian, Idaho
Showing 40 of 302 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.